UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for stomach cancer in the United Kingdom. Explore treatment pathways including immunotherapy, targeted therapy, and surgery.
Stomach cancer affects ~6,500 people per year in the UK. It often presents late with symptoms like indigestion, weight loss, nausea, and difficulty swallowing. Risk factors include H. pylori infection, smoking, high salt intake, and family history. HER2-positive stomach cancer (~20% of cases) responds to targeted therapy. Survival has improved with better surgery techniques and new systemic treatments.
Operable: perioperative chemotherapy (FLOT regimen) followed by surgery (gastrectomy). HER2-positive metastatic: trastuzumab + chemotherapy (first-line), with trastuzumab deruxtecan (T-DXd) as second-line (DESTINY-Gastric06). HER2-negative metastatic: immunotherapy + chemotherapy - nivolumab + FOLFOX/XELOX (CheckMate-649) or pembrolizumab for MSI-H tumours. Second-line options include ramucirumab + paclitaxel, and trifluridine-tipiracil.
Active UK stomach cancer trials include: novel immunotherapy combinations, ADCs targeting CLDN18.2 (zolbetuximab), bispecific antibodies, neoadjuvant immunotherapy, and biomarker-driven approaches. The NHS has specialist upper GI cancer centres with multidisciplinary teams.
Free AI-powered matching - no signup required
Search gastric cancer Trials →